ImetelChat

But tomorrow will be an important, nay seminal, day in Geron’s history. The very first presentation of a randomized double blinded phase III study with remarkable, unprecedented results. The presenter, Dr. Zeidan is a world renown researcher stationed at a world renowned institution (Yale). What a r...

A beautiful post. Thanks for sharing. I think we will see substantial and important PR from ASCO and EHA. Yale has signed on in a big way. All the major contributors to this study will get some much deserved credit. Not to mention Geron.

I am not planning to attend the shareholders meeting tomorrow. Would appreciate if anyone can post a summary. Thanks bp

Kmall and realize, well you have one day to get that question put to the board. Dr. Scarlett switched lanes countless times regarding partnerships over the years. My read (my opinion only) is that as the data continues to strengthen and with money in the bank amounting to several hundred million, he...

Hi Aron, hope you are well. It appears things are in full swing at Geron. This year I have only one (!) question for consideration at the annual shareholders meeting: As we as shareholders try to understand the implications of “disease modification”, does Geron see data developing to support a reduc...

An article several years ago, authored by Dr Steensma and others highlighted the non heme causes of death in myeloproliferative diseases, particularly due to cardiovascular causes thought to be due to active vascular inflammation that accompanies many cancers. An upcoming EHA presentation looks at t...

“ Treatment-related AEs were reported by 54 (30.3%) luspatercept and 31 (17.6%) epoetin alfa pts. AML progression was reported in 4 (2.2%) luspatercept and 5 (2.8%) epoetin alfa pts. Overall rates of death were comparable between arms during treatment and post-treatment (32 [18.0%] luspatercept, 32 ...

I myself, being an ancient one…

Most small biotechs would probably not announce when they file, only when they were accepted, for fear of subsequent rejection and the loss of face that would inevitably follow. Geron on the other hand is heads up, here it is. We file in June. Take from that what you will. Sincerest best wishes to a...

First formal presentation at major meeting and includes evidence for disease modification: https://ir.geron.com/investors/press-releases/press-release-details/2023/Geron-Oral-Presentation-at-Upcoming-ASCO-Annual-Meeting-to-Highlight-Meaningful-Continuous-Transfusion-Independence-Observed-in-Imetelst...

Note this important addition to the cast of usual suspects:

Catriona Jameison

Good timing:

https://ashpublications.org/bloodadvanc ... 903/495950

TLR results were announced 5 months ago in January. This is the first scientific meeting since then with a formal oral presentation. I can not believe this data would not be afforded a highlighted session but I guess we just don’t know yet. In any case the presenters are allowed usually to update da...

I have serious doubts they even exist in any meaningful form anymore. They did sell Astragalus root extract. Dr. Scarlett gave them a wide berth. File under snake oil.

Note primary results in Jan 2024. That’s in 8 months.

Jingle, I remember it well. Perhaps he will have some second thoughts.

FC, you might want to check the FDA calendar yourself.

Guess they are saving it for ASH.

KT, Careful this could end up costing 1.98 (to someone).

Kmall, I will PM you my address so you can get the envelope ready. Please also send me yours, just in case.